Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15474169 | 0.85 | APAF1 (0.37) | MTNR1AMTNR1BAPAF1CYP2D6CYP2C19 | |
| SCHEMBL24447196 | 0.84 | MTNR1A (0.42) | MTNR1AMTNR1BCYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL18125961 | 0.82 | CYP2D6 (0.64) | APAF1CYP2D6CYP2C19GABRR1CYP1A2 | |
| SCHEMBL15044013 | 0.82 | CYP2D6 (0.64) | APAF1CYP2D6CYP2C19GABRR1CYP1A2 | |
| SCHEMBL11505440 | 0.81 | APAF1 (0.47) | APAF1CYP2D6CYP2C19GABRR1CYP1A2 | |
| SCHEMBL2878498 | 0.79 | MTNR1A (0.42) | MTNR1AMTNR1BCYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL1331722 | 0.78 | GABRR1 (0.44) | APAF1CYP2D6CYP2C19GABRR1CYP1A2 | |
| SCHEMBL3994596 | 0.78 | APAF1 (0.41) | APAF1CYP2D6CYP2C19GABRR1CYP1A2 | |
| SCHEMBL10056838 | 0.78 | GABRR1 (0.44) | APAF1CYP2D6CYP2C19GABRR1CYP1A2 | |
| SCHEMBL10055164 | 0.78 | GABRR1 (0.44) | APAF1CYP2D6CYP2C19GABRR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3039068-B1 | MOISTURE CURABLE COMPOUND WITH AMINO ACIDS | MOMENTIVE PERFORMANCE MAT INC (US) | 2020-12-16 | — | — | EP | claimed |
| US-9914809-B2 | Moisture curable composition with amino acids | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2018-03-13 | — | — | US | claimed |
| US-20160200880-A1 | MOISTURE CURABLE COMPOSITION WITH AMINO ACIDS | MOMENTIVE PERFORMANCE MATERIALS INC. | 2016-07-14 | — | — | US | claimed |
| US-RE44302-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-06-18 | — | — | US | claimed |
| US-RE44017-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-02-19 | — | — | US | claimed |
| US-RE42902-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2011-11-08 | — | — | US | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-RE41278-E1 | N-acetyl aldosamines and related N-acetyl compounds, and their topical use | TRISTRATA, INC. | 2010-04-27 | — | — | US | claimed |
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-2080504-A2 | Topical composition comprising n-acetylaldosamines or n-acetylamino acids | Yu, Ruey J. (US) | 2009-07-22 | — | — | EP | claimed |
| WO-2009067541-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-05-28 | — | — | WO | claimed |
| US-20080214649-A1 | Compositions and Therapeutic Use of N-Acetyl Aldosamines and N-Acetylamino Acids | YU RUEY J | 2008-09-04 | — | — | US | claimed |
| WO-2006036634-A2 | SYSTEMIC ADMINISTRATION OF THERAPEUTIC AMINO ACIDS AND N-ACETYLAMINO ACIDS | YU RUEY J (US) | 2006-04-06 | — | — | WO | claimed |
| EP-1639994-A2 | Topical composition comprising N-acetylaldosamines or N-acetylamino acids | Yu, Ruey J., Dr. (US) | 2006-03-29 | — | — | EP | claimed |
| US-20060063827-A1 | Systemic administration of therapeutic amino acids and N-acetylamino acids | YU RUEY J | 2006-03-23 | — | — | US | claimed |
| EP-1570840-A2 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2005-09-07 | — | — | EP | claimed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | claimed |
| US-6524593-B1 | Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails | TRISTRATA, INC. | 2003-02-25 | — | — | US | claimed |
| US-6159485-A | COSMETICS; SKIN DISORDERS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-12-12 | — | — | US | claimed |
| WO-2000040217-B1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-10-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | TYMP, DNTT, PAICS | MTNR1A 4648/4885MTNR1B 4650/4885APAF1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.